Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6088154 | 0.87 | SLC2A1 (0.40) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL6086853 | 0.84 | GAA (0.50) | POLA1NPY5RTP53SMN1; SMN2MEN1 | |
| SCHEMBL6235697 | 0.84 | NPY5R (0.39) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL6235120 | 0.84 | NPY5R (0.47) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL6231257 | 0.82 | MEN1 (0.42) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL6233510 | 0.80 | MAPK14 (0.41) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL6235953 | 0.78 | ACP1 (0.43) | TP53SMN1; SMN2ACP1MEN1KMT2A | |
| SCHEMBL6091625 | 0.77 | NPY5R (0.57) | POLA1NPY5RTP53SMN1; SMN2ACP1 | |
| SCHEMBL19610596 | 0.76 | ACP1 (0.46) | ACP1PTK6ABCG2EGFRERBB2 | |
| SCHEMBL6235371 | 0.75 | MAPT (0.42) | POLA1NPY5RTP53SMN1; SMN2ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | POLA1 4751/4885NPY5R 374/4885TP53 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.